Trial record 5 of 161 for:    "Tachycardia, Ventricular" OR "catecholaminergic polymorphic ventricular tachycardia"

Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Avrimin M Kogan, MD, New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01901575
First received: April 16, 2013
Last updated: July 12, 2013
Last verified: July 2013
  Purpose

Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin


Condition Intervention
Tachycardia, Ventricular
Drug: Remifentanil

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Inhibition of idiopathic ventricular tachycardia [ Time Frame: during procedure ] [ Designated as safety issue: No ]
    observation of the anesthetic effect on the inhibition of the ventricular tachycardia in patients undergoing radio-frequency ablation of idiopathic ventricular tachycardia (RV0T)


Enrollment: 25
Study Start Date: July 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Remifentanil IV PCA Drug: Remifentanil

Detailed Description:

The purpose of the study is to determine the effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.

Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly broken down by enzymes in the blood and is ideally suited for continuous sedation. The effect is practically eliminated within 5 minutes after the intravenous sedation is stopped.

You are being asked to participate in this study because you are already scheduled to undergo EP studies under the care of your cardiologist for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin
  • Patients between 18 and 65
  • ASA 1-3

Exclusion Criteria:

  • ASA 4 and 5
  • Age 18 and 65
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01901575

Locations
United States, New York
NYU Langone Medical Center
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Investigators
Principal Investigator: Misha Kogan, MD NYU School of Medicine
  More Information

Publications:
Responsible Party: Avrimin M Kogan, MD, Clinical Assistant Professo, New York University School of Medicine
ClinicalTrials.gov Identifier: NCT01901575     History of Changes
Other Study ID Numbers: 11-00800
Study First Received: April 16, 2013
Last Updated: July 12, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by New York University School of Medicine:
ideopathic ventricular tachycardia

Additional relevant MeSH terms:
Tachycardia, Ventricular
Tachycardia
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Remifentanil
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Anesthetics

ClinicalTrials.gov processed this record on September 11, 2014